“The second quarter of 2023 was intensive and eventful for AlzeCure Pharma. During the quarter, we presented positive proof-of-mechanism (POM) results from our Phase II clinical study with ACD440 for the treatment of neuropathic pain. In addition, we published new preclinical data for our clinical drug candidate NeuroRestore ACD856 that supports both neuroprotective and disease modifying effects, both of which are relevant in the treatment of Alzheimer’s disease and other neurodegenerative diseases. We also had new patents granted in Europe for NeuroRestore, including ACD856, to be added to the previously approved patents for the US. It is gratifying to see that we are keeping up the pace as we continue to meet our set targets and generate new data that strengthen our position, while also paving the way for new opportunities.”

Martin Jönsson, CEO

Financial information for April – June, 2023
Figures in parentheses refer to the corresponding period of the previous year.

• Net sales during the period totaled SEK 0 thousand (0).
• Loss for the period totaled SEK -10,211 thousand (-21,548).
• Earnings per share, basic, totaled SEK -0.16 (-0.43).
• Cash flow from operating activities totaled SEK -8,906 thousand (23,188).
• Total assets at the end of the period amounted to SEK 48,119 thousand (55,303).
• Cash and cash equivalents at the end of the period totaled SEK 45,232 thousand (51,673).

Financial information for January – June, 2023
Figures in parentheses refer to the corresponding period of the previous year.

• Net sales during the period totaled SEK 0 thousand (0).
• Loss for the period totaled SEK -19,756 thousand (-34,194).
• Earnings per share, basic, totaled SEK -0.32 (-0.77).
• Cash flow from operating activities totaled SEK 19,189 thousand (-34,213).
• Total assets at the end of the period amounted to SEK 48,119 thousand (55,303).
• Cash and cash equivalents at the end of the period totaled SEK 45,232 thousand (51,673).

Significant events during the period April – June, 2022

• In April, the company has an abstract on non-opioid ACD440 for neuropathic pain accepted at the EFIC 2023 Conference.
• On May 17, the company holds its Annual General Meeting and Dr Janet Hoogstraate is elected to serve as a new member of the Board of Directors.
• The company announces on May 22 that a European patent has been granted for the NeuroRestore ACD856 Alzheimer’s project.
• On May 24 the company announces positive proof-of-mechanism (POM) data from the Phase IIa clinical trial in neuropathic pain with the non-opioid ACD440.

Significant events during the period January – March, 2023

• In January, the company chose a candidate drug (CD) and initiated the preclinical development phase with the company’s preventive and disease-modifying drug candidate Alzstatin ACD680.
• In January, the last patient was included in the Phase II clinical trial with the leading non-opioid drug candidate in the Painless platform, ACD440, which is being developed to treat peripheral neuropathic pain.
• The company announces on March 13 that the last patient has completed treatment in the above clinical trial with ACD440.

Significant events after the end of the period

• In July, the company publishes new disease modifying data with NeuroRestore ACD856 against Alzheimer’s and cognitive disorders.
• In July the company also publishes a new scientific article on preclinical results supporting antidepressive effects with NeuroRestore ACD856.

The full report is attached as PDF and is available on the company’s website: www.alzecurepharma.com/en/section/investors/financial-reports/